Citations

Clear

1792 citation(s) found for "Stephanie".

Single Cell Approaches Reveal Perturbed Brain Vascular Molecules in Alzheimer’s Disease
İş, Özkan , Wang, Xue , Reddy, Joseph S. , Min, Yuhao , Quicksall, Zachary , White, Launia J. , Deniz, Kaancan , Tutor‐New, Frederick Q, Carnwath, Troy , Oatman, Stephanie R., Carrasquillo, Minerva M. , Nguyen, Thuy , Petersen, Ronald C. , Allen, Mariet , Ertekin‐Taner, Nilüfer , Patel, Tulsi , Heckman, Michael G. , Kouri, Naomi , Carrasquillo, Minerva M. , Kantarci, Kejal , Nho, Kwangsik T. , Saykin, Andrew J. , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S4 | Pages: No page available

10.1002/alz.063202 Get It

AbstractBackgroundInter‐cellular communication within the gliovascular unit (GVU) is critical for cerebral blood flow regulation, maintenance of the blood‐brain‐barrier (BBB) properties, and brain energy metabolism. Although numerous cell biology studies demonstrate the role of the GVU for BBB breakdown in Alzheimer’s disease (AD), the precise molecular changes contributing to its pathophysiology are unclear.MethodWe performed single nucleus RNA sequencing (snRNAseq) of temporal cortex tissue in 24 AD and control brains to understand the transcriptional changes in the cells of GVU. We acquired the snRNAseq profile of 79,751 total brain cells that comprise 6,541 astrocytes and 2,210 vascular cells. The latter formed three distinct vascular clusters characterized as activated pericytes, endothelia and resting pericytes. We identified differentially expressed genes (DEGs) and their enriched pathways in these clusters and detected the most transcriptional changes within activated pericytes. Using our data and a knowledge‐based predictive algorithm, we discovered and prioritized molecular interactions between vascular and astrocyte clusters, the main cell types of the GVU of the BBB.ResultsVascular targets predicted to interact with astrocytic ligands have biological functions in signalling, angiogenesis, amyloid ß metabolism and cytoskeletal structure. Top astrocytic and vascular interacting molecules include both novel and known AD risk genes such as APOE, APP and ECE1. We validated gene expression changes using qPCR. We are in the process of evaluating these gene expression changes in antemortem blood from AD and control participants.ConclusionOur findings provide valuable information into the transcriptional changes in predicted vascular‐astrocytic partners at the GVU, highlighting insights into the molecular mechanisms of BBB breakdown in AD.
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains.
Schultz, Stephanie A. , Fagan, Anne M. , Hanseeuw, Bernard , Gordon, Brian A. , Chen, Charles D., Xiong, Chengjie , Fitzpatrick, Colleen , Chui, Helena C., Mori, Hiroshi , Morris, John C. , Johnson, Keith A., Liu, Lei , Farlow, Martin R. , Farrell, Michelle E. , Graff‐Radford, Neill R. , Perrin, Richard J. , Berman, Sarah , Salloway, Stephen , Shirzadi, Zahra , Bateman, Randall J. , Chhatwal, Jasmeer P. , Gordon, Brian A , Bateman, Randall J , Xiong, Chengjie , Morris, John C , Berman, Sarah , Allegri, Ricardo , Schultz, Aaron P. , Goate, Alison , Levey, Allan I. , Koeppe, Robert A. , Cruchaga, Carlos , Karch, Celeste M. , Xiong, Chengjie , Jack, Clifford R. , McDade, Eric , Chui, Helena C. , Lee, Jae‐Hong , Noble, James M. , Hassenstab, Jason , Johnson, Keith A. , Jucker, Mathias , Joseph‐Mathurin, Nelly , Fox, Nick C. , Schofield, Peter R. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Rosa-Neto, Pedro , Benzinger, Tammie L.S. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.068221 Get It

AbstractBackgroundRates of cognitive and biomarker change in Autosomal Dominant Alzheimer disease (ADAD) vary substantially across individuals. Prior cross‐sectional work suggests that the location of the pathogenic variant within PSEN1, specifically whether the underlying variant affects transmembrane (TM) or cytoplasmic (CY) domains in PSEN1, may be a key determinant in these differential rates of progression. Here we use longitudinal data from the Dominantly Inherited Alzheimer Network observational study (DIAN‐Obs) to examine whether variants affecting TM versus CY domains in PSEN1 have differential rates of change in key cognitive and neurodegenerative markers, and whether these differences are relevant to ADAD clinical trials.MethodsUsing longitudinal clinical, cognitive, and MRI data from PSEN1 pathogenic variant carriers [TM group N=76 and CY group N=44; Table 1], we assessed rates of change in Mini‐Mental State Exam (MMSE), Clinical Dementia Rating® Sum of Boxes (CDR®‐SOB), and hippocampal volume (HV) using linear mixed effects models accounting for disease stage (estimated years to symptom onset [EYO]). We further assessed how PSEN1 mutation location (TM versus CY) impacts sample size and detectable effect size in a potential ADAD clinical trial (modeled as a 4‐year trial with annual assessments; 80% power; α = 0.05).Results PSEN1 TM and PSEN1 CY groups did not differ on baseline age, EYO, or CDR®. The PSEN1 TM group had significantly greater rates of change on MMSE (B[SE] = ‐0.42[0.1], p=0.002), CDR®‐SOB (B[SE] = 0.23[0.1], p=0.001), and HV atrophy (B[SE] = ‐58.93[14.3], p=0.0006 compared to the PSEN1 CY group (Fig.1). Consistent with these differential rates of change, power analyses indicated the required sample size to detect a 30% treatment effect on MMSE or HV would be reduced by 59.6% for MMSE and 91.0% for HV for a trial population comprised of PSEN1 TM versus CY carriers (Fig.2).ConclusionsIndividuals who had a variant affecting the transmembrane domains of PSEN1 had greater rates of cognitive decline and neurodegeneration compared to those with variants affecting cytoplasmic domains. In addition to having implications for ADAD pathophysiology, these results suggest that incorporating information regarding the location of PSEN1 variants may be beneficial in analyzing and designing stratification approaches for ADAD trials.
Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Tempero, Margaret A. , Pelzer, Uwe , Oh, Do‐Youn , Li, Chung‐Pin , Tortora, Giampaolo , Chang, Heung-Moon, Lopez, Charles D. , Bekaii‐Saab, Tanios , Ko, Andrew H. , Santoro, Armando , Noel, Marcus Smith , Dean, Andrew , Riess, Hanno, Philip, Philip, Moore, Malcolm J. , Goldstein, David , Ferrara, Stefano, Bruchec, Yvan Le, Lu, Brian , Epstein, Richard A. , Vasey, Paul L., Shapiro, Jeremy, Burge, Matthew , Chua, Yu Jo , Harris, Marion , Prager, Gerald W. , Dittrich, Christian , Längle, Friedrich, Philipp‐Abbrederis, Kathrin, Greil, Richard , Stöger, Herbert, Girschikofsky, Michael , Kuehr, Thomas, Laethem, Jean–Luc Van, Laurent, Stéphanie , Ko, Yoo Joung, Dowden, Scot, Kavan, Petr , Tehfe, Mustapha Édouard, Kubala, Eugen, Kohoutek, Milan, Yilmaz, Mette, Parner, Vibeke K., Salminen, Tapio , Soveri, Leena‐Maija , Korkeila, Eija, Taı̈eb, Julien , Artru, Pascal , Guimbaud, Rosine , Turpin, Antony, Kunzmann, Volker , Kreth, Florian, Oettle, Helmut, Karthaus, Meinolf , Folprecht, Gunnar , Kullmann, Frank , Reiser, Marcel , Heinemann, Volker , Wörns, Marcus‐Alexander , Schulz, H. , Garlipp, Benjamin , Chan, Lam Stephen, Juhász, Balázs , Landherr, László, Pintér, Tamás , Kahán, Zsuzsanna , McDermott, Raymond, Power, Derek G. , Siena, Salvatore, Milella, Michèle , Bagalá, Cinzia, Roila, Fausto, Fanello, Silvia, Wilmink, Johanna W. , Groot, Jan Willem de, Creemers, G.J., Rodrigues, Tânia , Tai, David , Mercadé, T. Macarulla, Medina, Manuel Hidalgo, Mena, Alfredo Carrato, Santasusana, Joan Maurel, Oncala, Maria Jose Flor, Martín, Carlos Gómez , Muñoz, Andrés, García, Ruth Vera, Alés, Inmaculada, Rivera, Fernando , Sastre, Javier , Wu, Cheng‐Chung, Tien, Yu‐Wen , Chan, De-Chuan , Hwang, Tsann‐Long , Evans, Jeffry, Wadsley, Jonathan , Chiorean, E. Gabriela , Bendell, Johanna C. , Kindler, Hedy L. , Fernando, Nishan H., Beg, Muhammad Shaalan , LoConte, Noelle K. , Posey, James , Malhotra, Rajat, Sohal, Davendra , Brenner, Warren, Womack, Mark, Seth, Rahul , lyer, Renuka, Bahary, Nathan , Marsh, Robert , Chua, Cynthia C., Reeves, J. N. , Manji, Gulam A. , Sahai, Vaibhav , Messersmith, Wells A. , Zakari, Ahmed, Bullock, Andrea J. , Musher, Benjamin , Kim, Edward , Bajor, David J., Huyck, Tim, Hatoum, Hassan , Xiong, Henry, Pasche, Boris , Lacy, Jill , Olowokure, Olugbenga, Cohn, Allen Lee, Richards, Donald , Martin, Robert C.G. , Paulson, Andrew Scott , Fanta, Paul T. , Krishnamurthi, Smitha , Fuloria, Jyotsna, McDermott, Ray , Turpin, Anthony , O'Reilly, Eileen M , Winter, Jordan Michael , Oh, Do-Youn , Li, Chung-Pin , Tortora, Giampaolo , Bekaii-Saab, Tanios S , Santoro, Armando , Park, Joon Oh , Dean, Andrew , Van Cutsem, Eric , Berlin, Jordan D. , Tabernero, Josep , Biankin, Andrew V , LoConte, Noelle , Taieb, Julien , McDermott, Ray , Prager, Gerald W , Sahai, Vaibhav , O’Reilly, Eileen M. , Frassineti, Giovanni Luca , Shan, Yan‐Shen , Cutsem, Eric Van , Tabernero, Josep , Li, Mingyu , Zhang, George , Biankin, Andrew V. , Reni, Michele , Vasey, Paul, Pavlakis, Nick , Tebbutt, Niall C. , Längle, Friedrich, Dhani, Neesha C. , Tehfe, Mustapha , Pfeiffer, Per , Osterlund, Pia J. , Tougeron, David , Caroli‐Bosc, François‐Xavier , Walter, Thomas , Bachet, Jean‐Baptiste , Block, Andreas, Venerito, Marino , Trojan, Jörg , Lerch, Markus M. , Schulz, Holger, Yau, Thomas , Juhasz, Balazs, Bodoky, Gyorgy , Gianni, Luca , Siena, Salvatore , Falcone, Alfredo , Berardi, Rossana , Costanzo, Francesco Di , Ardizzoni, Andrea , Maiello, Evaristo , Barroso, Eduardo , Sarmento, Cristina, Chee, Cheng Ean , López López, Rafael , Sáez, Berta Laquente, Chan, De‐Chuan , Evans, Jeffry, Corrie, Pippa G. , Cardin, Dana B. , Noonan, Anne M. , George, Thomas J. , Arena, Francis P. , McWilliams, Robert R. , Seth, Rahul, Ramirez, Robert A. , Reeves, James, El-Khoueiry, Anthony B. , Weaver, Robert, Dreicer, Robert , Borad, Mitesh J. , Huyck, Timothy K., Xiong, Henry Q., Oberstein, Paul E.

Mayo Clinic

Journal of Clinical Oncology | December 15, 2022 | Volume: 41 | Issue: 11 | Pages: 2007-2019

10.1200/jco.22.01134 | PMID 36521097 Get It

PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METHODS We assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to nab-paclitaxel (125 mg/m 2 ) + gemcitabine (1,000 mg/m 2 ) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles. The primary end point was independently assessed disease-free survival (DFS). Additional end points included investigator-assessed DFS, overall survival (OS), and safety. RESULTS Two hundred eighty-seven of 432 patients and 310 of 434 patients completed nab-paclitaxel + gemcitabine and gemcitabine treatment, respectively. At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently assessed DFS was 19.4 ( nab-paclitaxel + gemcitabine) versus 18.8 months (gemcitabine; hazard ratio [HR], 0.88; 95% CI, 0.729 to 1.063; P = .18). The median investigator-assessed DFS was 16.6 (IQR, 8.4-47.0) and 13.7 (IQR, 8.3-44.1) months, respectively (HR, 0.82; 95% CI, 0.694 to 0.965; P = .02). The median OS (427 events; 68% mature) was 40.5 (IQR, 20.7 to not reached) and 36.2 (IQR, 17.7-53.3) months, respectively (HR, 0.82; 95% CI, 0.680 to 0.996; P = .045). At a 16-month follow-up (cutoff, April 3, 2020; median follow-up, 51.4 months [IQR, 47.0-57.0]), the median OS (511 events; 81% mature) was 41.8 ( nab-paclitaxel + gemcitabine) versus 37.7 months (gemcitabine; HR, 0.82; 95% CI, 0.687 to 0.973; P = .0232). At the 5-year follow-up (cutoff, April 9, 2021; median follow-up, 63.2 months [IQR, 60.1-68.7]), the median OS (555 events; 88% mature) was 41.8 versus 37.7 months, respectively (HR, 0.80; 95% CI, 0.678 to 0.947; P = .0091). Eighty-six percent ( nab-paclitaxel + gemcitabine) and 68% (gemcitabine) of patients experienced grade ≥ 3 treatment-emergent adverse events. Two patients per study arm died of treatment-emergent adverse events. CONCLUSION The primary end point (independently assessed DFS) was not met despite favorable OS seen with nab-paclitaxel + gemcitabine.
Microsurgical Obliteration of Craniocervical Junction Dural Arteriovenous Fistulas: Multicenter Experience
Salem, Mohamed M. , Srinivasan, Visish M. , Ravindran, Krishnan , Yang, Kaiyun , Karahalios, Katherine , Raygor, Kunal P. , Naylor, Ryan M. , Tavakoli, Samon , Abdelsalam, Ahmed , Chen, Stephanie H. , Jankowitz, Brian T. , Başkaya, Mustafa K. , Cherian, Jacob , Kim, Louis J. , Starke, Robert M., Kan, Peter , Dehdashti, Amir R. , Abla, Adib A. , Lawton, Michael T. , Burkhardt, Jan‐Karl , Abla, Adib , Burkhardt, Jan‐Karl , Tonetti, Daniel A. , Taussky, Philipp , Catapano, Joshua S , Grandhi, Ramesh , Mascitelli, Justin R , Gompel, Jamie J. Van , Couldwell, William T. , Kim, Louis J. , Cohen‐Gadol, Aaron

Mayo Clinic

Neurosurgery | December 15, 2022 | Volume: 92 | Issue: 1 | Pages: 205-212

10.1227/neu.0000000000002196 | PMID 36519864 Get It

BACKGROUND: Dural arteriovenous fistulas (dAVFs) located at craniocervical junction are extremely rare (1%-2% of intracranial/spinal dAVFs). Their angio-architectural complexity renders endovascular embolization to be challenging given multiple small feeders with risk of embolysate reflux into vertebral artery and limited transvenous access. The available literature discussing microsurgery for these lesions is limited to few case reports. OBJECTIVE: To report a multicenter experience assessing microsurgery safety/efficacy. METHODS: Prospectively maintained registries at 13 North American centers were queried to identify craniocervical junction dAVFs treated with microsurgery (2006-2021). RESULTS: Thirty-eight patients (median age 59.5 years, 44.7% female patients) were included. The most common presentation was subarachnoid/intracranial hemorrhage (47.4%) and myelopathy (36.8%) (92.1% of lesions Cognard type III-V). Direct meningeal branches from V3/4 vertebral artery segments supplied 84.2% of lesions. All lesions failed (n = 5, 13.2%) or were deemed inaccessible/unsafe to endovascular treatment. Far lateral craniotomy was the most used approach (94.7%). Intraoperative angiogram was performed in 39.5% of the cases, with angiographic cure in 94.7% of cases (median imaging follow-up of 9.2 months) and retreatment rate of 5.3%. Favorable last follow-up modified Rankin Scale of 0 to 2 was recorded in 81.6% of the patients with procedural complications of 2.6%. CONCLUSION: Craniocervical dAVFs represent rare entity of lesions presenting most commonly with hemorrhage or myelopathy because of venous congestion. Microsurgery using a far lateral approach provides robust exposure and visualization for these lesions and allows obliteration of the arterialized draining vein intradurally as close as possible to the fistula point. This approach was associated with a high rate of angiographic cure and favorable clinical outcomes.
Case Report of a Diabetic Foot Infection Caused by Staphylococcus pseudintermedius, a Zoonotic Pathogen of Canine Origin
Bobbitt, Kimberly L., Winder, Michelle , Kvas, Stephanie P.

Mayo Clinic

Journal of the American Podiatric Medical Association | December 14, 2022 | Volume: 112 | Issue: 6 | Pages: No page available

10.7547/21-114 | PMID 36525328 Get It

Staphylococcus pseudintermedius is an emerging zoonotic pathogen that is very similar to human Staphylococcus pathogens, particularly multidrug-resistant Staphylococcus aureus . Recent reports have indicated that S pseudintermedius is easily transmitted between pets (mainly dogs) and owners because of these similarities. Although this pathogen has been associated with diabetic foot infections, it has not yet been described in the podiatric medical literature. In this case report, we present a diabetic foot infection in a 61-year-old man that was refractory to multiple rounds of antibiotic drug therapy. Deep wound cultures eventually grew S pseudintermedius , which was the first known case of this pathogen reported in our hospital system.
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
Switchenko, Jeffrey M. , Bachanová, Veronika , Gerson, James N. , Gordon, Max J. , Danilov, Alexey V. , Grover, Natalie S. , Mathews, Stephanie , Burkart, Madelyn , Hill, Brian T. , Park, Steven , Fenske, Timothy S. , Martin, Peter W., Malecek, Mary‐Kate , Flowers, Christopher R. , Link, Brian K. , Kaplan, Lawrence D. , Inwards, David J. , Maddocks, Kami J. , Blum, Kristie A. , Bartlett, Nancy L. , Leonard, John P. , Cohen, Jonathon B. , Epperla, Narendranath , Switchenko, Jeffrey , Grover, Natalie S , Burkart, Madelyn , Karmali, Reem , Sawalha, Yazeed , Ghosh, Nilanjan , Park, Steven I , Bond, David A , Hamadani, Mehdi , Kahl, Brad S , Link, Brian K , Feldman, Andrew L , Hsi, Eric D , Bartlett, Nancy L , Cerhan, James R , Maurer, Matthew , Cohen, Jonathon B , Bachanova, Veronika , Epperla, Narendranath , Barta, Stefan K , Karmali, Reem , Sawalha, Yazeed , Bond, David A. , Hamadani, Mehdi , Martin, Peter, Kahl, Brad S. , Feldman, Andrew L. , Hsi, Eric D. , Cerhan, James R. , Habermann, Thomas M. , Maurer, Matthew J.

Mayo Clinic

Blood Advances | December 14, 2022 | Volume: 7 | Issue: 11 | Pages: 2287-2296

10.1182/bloodadvances.2022009225 | PMID 36516079 Get It

Abstract The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on outcomes in MCL using 3 large datasets (1) the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource, (2) patients enrolled in the ALL Age Asthma Cohort/CALGB 50403, and (3) a multisitecohort of patients with MCL. Patients were a priori divided into 2 groups, 0 to 14 days (short DTI) and 15 to 60 days (long DTI). The patients in whom observation was deemed appropriate were excluded. One thousand ninety-seven patients newly diagnosed with MCL and available DTI were included in the study. The majority (73%) had long DTI (n=797). Patients with short DTI had worse eastern cooperative oncology group performance status (ECOG PS ≥2), higher lactate dehydrogenase, bone marrow involvement, more frequent B symptoms, higher MCL International Prognostic Index (MIPI ≥6.2), and were less likely to receive intensive induction therapy than long DTI group. The median progression-free survival (2.5 years vs 4.8 years, p<0.0001) and overall survival (7.8 years vs. 11.8 years, p<0.0001) were significantly inferior in the short DTI group than the long DTI cohort and remained significant for progression-free survival and overall survival in multivariable analysis. We show that the DTI is an important prognostic factor in patients newly diagnosed with MCL and is strongly associated with adverse clinical factors and poor outcomes. DTI should be reported in all the patients newly diagnosed with MCL who are enrolling in clinical trials and steps must be taken to ensure selection bias is avoided.
Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia
Jin, Qi , Gutierrez-Diaz, Blanca T. , Zhou, Yalu, Narang, Sonali , Fijalkwoski, Igor, Borin, Cristina , Laere, Jolien Van, Payton, Monique A. , Cho, Byoung-Kyu , Han, Cuijuan , Sun, Limin , Serafin, Valentina , Yacu, George, Veltri, Giulia , Dreveny, Ingrid , Goo, Young Ah , Safgren, Stephanie L. , Tsai, Yi-Chien , Bornhäuser, Beat , Suraneni, Praveen, Gaspar‐Maia, Alexandre , Kandela, Irawati , Crispino, John D. , Ntziachristos, Panagiotis , Gutierrez Diaz, Blanca , Pieters, Tim , Narang, Sonali , Fijalkwoski, Igor , Borin, Cristina , Payton, Monique , Cho, Byoung-Kyu , Han, Cuijuan , Sun, Limin , Serafin, Valentina , Von Loocke, Wouter , Veltri, Giulia , Dreveny, Ingrid , Ben-Sahra, Issam , Safgren, Stephanie L , Bornhauser, Beat , Gaspar-Maia, Alexandre , Van Vlierberghe, Pieter , Tsirigos, Aristotelis , Ntziachristos, Panagiotis , Crispino, John D , Jin, Qi , Basso, Giuseppe , Vlierberghe, Pieter Van , Tsirigos, Aristotelis

Mayo Clinic

Science Advances | December 9, 2022 | Volume: 8 | Issue: 49 | Pages: No page available

10.1126/sciadv.abq8437 | PMID 36490346 Get It

Dysregulation of kinase signaling pathways favors tumor cell survival and therapy resistance in cancer. Here, we reveal a posttranslational regulation of kinase signaling and nuclear receptor activity via deubiquitination in T cell acute lymphoblastic leukemia (T-ALL). We observed that the ubiquitin-specific protease 11 (USP11) is highly expressed and associates with poor prognosis in T-ALL. USP11 ablation inhibits leukemia progression in vivo, sparing normal hematopoiesis. USP11 forms a complex with USP7 to deubiquitinate the oncogenic lymphocyte cell–specific protein-tyrosine kinase (LCK) and enhance its activity. Impairment of LCK activity leads to increased glucocorticoid receptor (GR) expression and glucocorticoids sensitivity. Genetic knockout of USP7 improved the antileukemic efficacy of glucocorticoids in vivo. The transcriptional activation of GR target genes is orchestrated by the deubiquitinase activity and mediated via an increase in enhancer-promoter interaction intensity. Our data unveil how dysregulated deubiquitination controls leukemia survival and drug resistance, suggesting previously unidentified therapeutic combinations toward targeting leukemia.
IBD Journal Editorial Fellowship: A Practical Guide for Future Fellows
Kurdi, Ahmed T. , Noor, Nurulamin M , Gold, Stephanie Lauren

Mayo Clinic

Inflammatory Bowel Diseases | December 9, 2022 | Volume: 29 | Issue: 1 | Pages: 172-173

10.1093/ibd/izac249 | PMID 36482778 Get It

Lay Summary Inflammatory Bowel Diseases offers an editorial fellowship for GI and IBD fellows with a background in clinical, translational, and basic research and who are interested to experience the editorial process. Herein, the inaugural fellows compile their experience as a guide for future applicants on the fellowship’s responsibilities and highlights.
Incidence of and Neurodevelopmental Outcomes After Late-Onset Meningitis Among Children Born Extremely Preterm
Bell, Edward F. , Barbara, T. , Greenberg, Rachel G. , Stoll, Barbara J. , DeMauro, Sara B. , Harmon, Heidi M. , Hintz, Susan R. , Das, Abhik , Puopolo, Karen M. , Bailey, Kirstin J., Biasini, Fred J., Chopko, Stephanie A., Collins, Monica V., Cosby, Shirley S., Johnston, Kristen C. , Moses, Mary Beth, Nelson, Kathleen G., Patterson, Cryshelle S., Peralta-Carcelén, Myriam , Phillips, Vivien A., Preskitt, Julie , Rector, Richard V., Whitley, Sally, Alksninis, Barbara, Bishop, Carmena, Burke, Robert T., Caskey, Melinda, Hensman, Angelita M. , Hoffman, Laurie , Johnson, Katharine, Keszler, Mary Lenore, Knoll, Andrea M., Lamberson, Vita, Laptook, Abbot R. , Leach, Theresa M., Little, Emilee, McGowan, Elizabeth C., Pierre, Lucille St., Stephens, Bonnie E., Ventura, Suzy, Vieira, Elisa , Vohr, Betty R. , Coleman, Kelly R., Guilford, Stephanie , Hartley-McAndrew, Michelle, Li, Emily, Reynolds, Anne Marie , Sacilowski, Michael G., Williams, Ashley, Zorn, William, Bhola, Monika , Fanaroff, Avroy A., Friedman, Harriet, Newman, Nancy S., Siner, Bonnie S., Walsh, Michele C. , Wilson-Costello, Deanne E. , Yalcinkaya, Gulgun, Caplan, Michael S. , Beiersdorfer, Traci , Bridges, Kate, Cahill, Tanya E., Donovan, Edward F., Dudley, Juanita , Fischer, Estelle E., Gratton, Teresa L., Grisby, Cathy, Hayes, Devan, Hessling, Jody, Jackson, Lenora, Kallapur, Suhas G. , Kirker, Kristin, Merhar, Stephanie L. , Mincey, Holly L., Muthig, Greg, Poindexter, Brenda B. , Schibler, Kurt, Stacey, Sara, Steichen, Jean J., Tepe, Stacey, Thompson, Julia, Mersmann, Marcia Worley, Wuertz, Sandra, Polin, Richard A. , Adams, Sally S., Leon, Maria Magdalena, Eubanks, Frances, Guzman, Alicia, Hensley, Gaynelle, Heyne, Elizabeth T., Heyne, Roy J. , Hickman, Jackie F., Lee, Lizette E. , Leps, Melissa H., Madden, Linda A., McDougald, E. Rebecca, Miller, Nancy A., Morgan, Janet S., Pavageau, Lara, Salhab, Walid A., Sepulveda, Pollieanna , Boatman, Catherine Twell, Vasil, Diana M., Waterbury, Jillian, Wyckoff, Myra H. , Ashley, Patricia L., Auten, Kathy J., Cotten, C. Michael , Finkle, Joanne, Fisher, Kimberley A. , Goldberg, Ronald N., Goldstein, Ricki F., Grimes, Sandra, Gustafson, Kathryn E. , Lohmeyer, Melody B., Malcolm, William , Adams‐Chapman, Ira , Blackwelder, Ann M., Bottcher, Diane I., Carlton, David P., Carter, Sheena L., Hale, Ellen C., Kendrick-Allwood, Salathiel, Laursen, Judith, Loggins, Yvonne, Mackie, Colleen, LaRossa, Maureen Mulligan, Sanders, Amy , Seabrook, Irma, Smikle, Gloria V., Wineski, Lynn, Akpa, Esther, Alaniz, Nora I., Allain, Elizabeth, Arldt-McAlister, Julie, Bradt, Pamela J., Burson, Katrina, Dieterich, Susan, Duncan, Andrea F. , Eason, Elizabeth, Evans, Patricia W., Harris, Beverly Foley, Franco, Claudia I., Garcia, Carmen, Hall, Donna J., Jiménez, Margarita, John, Janice , Jones, Patrick M., Kennedy, Kathleen A. , Siddiki, Saba Khan, Lillie, Layne M., Major-Kincade, Terri L., Martin, Sara C., McDavid, Georgia E., McKee, Shannon L. , Morris, Brenda H., Orekoya, Patricia Ann, Pedrozza, Claudia, Perez, Carrie M., Tate, Patti L. Pierce, Reddoch, Stacey, Rodgers, Shawna, Simmons, Maegan C., Sperry, Daniel K., Stephens, Emily K. , Tyson, Jon E., Whitely, Laura L., Wright, Sharon L., Dusick, Anna M., Gunn, Susan, Hamer, Faithe, Herron, Dianne E., Hines, Abbey C. , Joyce, Jeffery, Lemons, James A., Lytle, Carolyn, Miller, Lucy , Minnich, Heike M., Papile, L.A., Richard, Leslie, Smiley, Lucy, Sokol, Gregory M. , Wilson, Leslie Dawn, Acarregui, Michael J., Colaizy, Tarah T. , Eastman, Diane L., Goeke, Claire A., Johnson, Karen, Krutzfield, Nancy J., Schmelzel, Mendi L., Walker, Jacky R., Bass, Donia B., Ellsbury, Dan L., Tud, Tracy L., Bauer, Charles R., Duara, Shahnaz , Everett‐Thomas, Ruth , Fajardo-Hiriart, Sylvia, Eguaras, Silvia M. Frade, Garcia, Andrea, Berkovits, Michelle Harwood, Pierre, Helina, Riguard, Arielle, Stoerger, Alexandra, Gaetano, Lisa, Gauldin, Cheri, Holmes, Anne, Johnson, Kathy, Kilbride, Howard W. , Pallotto, Eugenia K. , Parimi, Prabhu S., Scott, Allison, Truog, William E., Besner, Gail E. , Clark, Erna, Gutentag, Julie, Jadcherla, Sudarshan R. , Luzader, Patricia, Park, Courtney, Shadd, Julie C., Stein, Melanie, Sullivan, Margaret, Bremer, Andrew A. , Higgins, Rosemary D. , Archer, Stephanie Wilson , Abbasi, Soraya, Bernbaum, Judy, Catts, Christine, Chaudhary, Aasma S. , Cucinotta, Dara M., Eichenwald, Eric C. , Gerdes, Marsha , Ghavam, Sarvin, Hurt, Hallam, Snyder, Jonathan, Vangala, Sarith, Ziolkowski, Kristina, Johnson, Julie Babish, Binion, Kyle, Bowman, Melissa, Burnell, Erica, D’Angio, Carl T., Fallone, Caitlin, Farooq, Osman , Guillet, Ronnie , Horihan, Cassandra A., Hunn, Julianne, Hust, Diane, Jensen, Rosemary L., Jones, Rachel , Kachelmeyer, Jennifer , Kushner, Emily, Maffett, Deanna, McKee, Kimberly G., Merzbach, Joan, Myers, Gary J. , Orme, Constance, Phelps, Dale L. , Dm, Prinzing, Reubens, Linda J., Rochez, Daisy, Rowan, Mary, Sabaratnam, Premini, Scorsone, Ann Marie, Wadkins, Holly I.M., Yost, Kelley, Zwetsch, Lauren, Gabrio, Jenna, Hastings, Betty K., LeBlond, David, Auman, Jeanette O’Donnell , Huitema, Carolyn M. Petrie , Poole, W. Kenneth, Wallace, Dennis, Zaterka-Baxter, Kristin M. , Baack, Michelle , Broadbent, Megan, Elenkiwich, Chelsey, Henning, Megan M., Hogden, Laurie A., Adams, Marian M. , Bahmani, Dona, Ball, M. Bethany , Bentley, Barbara, Bruno, Elizabeth F., Chock, Valerie Y. , Davis, Alexis S. , DeAnda, Maria Elena, DeBattista, Anne M., Earhart, Beth, Huffman, Lynne C. , Ismael, Magdy, Kohn, Jean G., Krueger, Casey E., Lee-Ancajas, Julie C., Lowe, Janice, Lucash, Ryan E., Palmquist, Andrew W., Patel, Jessica, Proud, Melinda S., Reichert, Elizabeth N., Sivakumar, Dharshi, John, Nicholas H. St., Stevenson, David K. , Meurs, Krisa P. Van , Wager, Natalie, Williams, R. Jordan , Weiss, Hali E., Brussa, Ana K. , Church, Paige , Fiascone, John M., Frantz, Ivan D. , Furey, Anne, Kurfiss, Anne, MacKinnon, Brenda L., McGowan, Elisabeth C. , Nylen, Ellen, Sibley, Cecelia, Chanlaw, Teresa , Devaskar, Uday, Garg, Meena, Geller, Rachel , Purdy, Isabell B., Arnell, Kathy, Demetrio, Clarence, Finer, Neil N., Fuller, Martha G. , Henderson, Christopher, Kaegi, David, Rasmussen, Maynard R., Rich, Wade , Vaucher, Yvonne E. , Wozniak, Paul R., Bernhardt, Janice, Bose, Carl , Bose, Gennie, Clark, Cynthia L., Warner, Diane, Wereszczak, Janice, Lacy, Conra Backstrom, Fuller, Janell, Hanson, Mary, Hartenberger, Carol H., Kuan, Elizabeth, Lowe, Jean, Ohls, Robin K. , Beauman, Sandra Sundquist , Thomson, Rebecca A., Watterberg, Kristi L. , Carlson, Martha, Christensen, Mary, Wiggins, Stephanie A., Baker, Shawna, Baserga, Mariana , Bird, Karie, Burnett, Jill, Christensen, Susan, Bledsoe, Laura Cole, Cunningham, Sean D. , Davis, Brandy, Elmont, Jennifer O., Faix, Roger G., Hall, Becky, Jensen, Erika R., Jensen, Jennifer J., Jordan, Jamie, Loertscher, Manndi C., Marchant, Trisha, Maxson, Earl, McGrath, Kandace M., Minton, Stephen D., Morshedzadeh, Galina, Osborne, Karen A., Parry, Dilys M. , Rau, Carrie A., Reich, Brixen A., Schaefer, Susan T., Sheffield, Mark J., Spencer, Cynthia, Steffen, Michael, Stout, Kelly, Stuart, Ashley L., Tice, Katherine, Weaver-Lewis, Kimberlee, Winter, Sarah , Woodbury, Kathryn D., Yoder, Bradley A. , Zanetti, Karen, Chiu, Korinne, Dillard, Robert G., Allred, Deborah Evans, Goldstein, Donald J., Halfond, Raquel, Jackson, Barbara G., O’Shea, T. Michael , Peters, Nancy, Peterson, Carroll, Waldrep, Ellen, Washburn, Lisa K. , Welch, Cherrie D. , Morris, Melissa Whalen, Hounshell, Gail, Kicklighter, Stephen D. , Rhodes-Ryan, Ginger, Abramczyk, Katherine, Agarwal, Prashant , Bajaj, Monika , Bara, Rebecca, Billian, Elizabeth, Chawla, Sanjay , Childs, Kirsten, Jesus, Lilia C. De, Driscoll, D., February, Melissa, Goldston, Laura A., Muran, Geraldine, Natarajan, Girija , Pappas, Athina, Prentice, Jeannette E., Shankaran, Seetha , Sood, Beena G. , White, Diane F., Woldt, Eunice, Butler, Christine G., Cervone, Patricia, Ehrenkranz, Richard A., Gettner, Patricia, Greisman, Sheila, Jacobs, Harris C., Konstantino, Monica, Poulsen, JoAnn, Romano, Elaine, Taft, Janet, Brumbaugh, Jane E. , Das, Abhik , Baack, Michelle L , Ambalavanan, Namasivayam , Carlo, Waldemar A. , Keszler, Martin , Oh, William, Watson, Victoria E. , Lakshminrusimha, Satyan , Hibbs, Anna Maria , Payne, Allison H. , Alexander, Barbara D. , Jobe, Alan Hall , Yolton, Kimberly , Brion, Luc P. , Chen, Lijun , Leon, Maria M. De, Miller, Nancy A., Rosenfeld, Charles R. , Sánchez, Pablo J. , Patel, Ravi M. , Dempsey, Allison G. , Green, Charles E. , Khan, Amir M , Lis, Anna E. , Martin, Karen , Dagle, John M. , Klein, Jonathan M. , Widness, John A. , Calejo, Maria, Fortney, Christine A. , Maitre, Nathalie L. , Nelin, Leif Daniel , Parikh, Nehal A. , Cook, Noah , Kirpalani, Haresh Murli , Mancini, Toni, Schmidt, Barbara Kristina , Vangala, Saritha, Kent, Alison , Sabaratnam, Premini , Bann, Carla , Crawford, Margaret M. , Gantz, Marie G. , Leblond, David, Newman, Jamie E. , Taylor, Heather Lee , Henderson, Christopher, Laughon, Matthew Maxwell , DuPont, Tara L. , Barks, John , Sarkar, Subrata , Parry, D. Melody, Spencer, Cynthia, Steffen, Michael, White, Donna, Johnson, Mary E. , Panaitescu, Bogdan , Williams, Joanne W.

Mayo Clinic

JAMA Network Open | December 8, 2022 | Volume: 5 | Issue: 12 | Pages: e2245826

10.1001/jamanetworkopen.2022.45826 | PMID 36480199 Get It

ImportanceLate-onset meningitis (LOM) has been associated with adverse neurodevelopmental outcomes in children born extremely preterm.ObjectiveTo report the incidence of LOM during birth hospitalization and neurodevelopmental outcomes at 18 to 26 months’ corrected age.Design, Setting, and ParticipantsThis cohort study is a secondary analysis of a multicenter prospective cohort of children born at 22 to 26 weeks’ gestation between 2003 and 2017 with follow-up from 2004 to 2021. The study was conducted at 25 Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network centers.ExposuresCulture-confirmed LOM.Main Outcomes and MeasuresIncidence and microbiology of LOM (2003-2017); lumbar puncture (LP) performance in late-onset sepsis (LOS) evaluations (2011-2017); composite outcome of death or neurodevelopmental impairment (NDI; 2004-2021).ResultsAmong 13 372 infants (median [IQR] gestational age, 25.4 [24.4-26.1] weeks; 6864 [51%] boys), LOM was diagnosed in 167 (1%); LOS without LOM in 4564 (34%); and neither LOS nor LOM in 8641 (65%). The observed incidence of LOM decreased from 2% (95% CI, 1%-3%) in 2003 to 0.4% (95% CI, 0.7%-1.0%) in 2017 (P < .001). LP performance in LOS evaluations decreased from 36% (95% CI, 33%-40%) in 2011 to 24% (95% CI, 21%-27%) in 2017 (P < .001). Among infants with culture-confirmed LOS, LP performance decreased from 58% (95% CI, 51%-65%) to 45% (95% CI, 38%-51%; P = .008). LP performance varied by center among all LOS evaluations (10%-59%, P < .001) and among those with culture-confirmed LOS (23%-79%, P < .001). LOM occurred in the absence of concurrent LOS in 27 of 167 cases (16%). The most common LOM isolates were coagulase-negative Staphylococcus (98 [59%]), Candida albicans (38 [23%]), and Escherichia coli (27 [16%]). Death or NDI occurred in 22 of 46 children (48%) with LOM due to coagulase-negative Staphylococcus, 43 of 67 (64%) due to all other bacterial pathogens, and 26 of 33 (79%) due to fungal pathogens. The adjusted relative risk of death or NDI was increased among children with LOM (aOR, 1.53; 95% CI, 1.04-2.25) and among those with LOS without LOM (aOR, 1.41; 95% CI, 1.29-1.54) compared with children with neither infection.Conclusions and RelevanceIn this cohort study, LP was performed with decreasing frequency, and the observed incidence of LOM also decreased. Both LOM and LOS were associated with increased risk of death or NDI; risk varied by LOM pathogen. The full association of LOM with outcomes of children born extremely preterm may be underestimated by current diagnostic practices.
Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results
Macklin‐Mantia, Sarah K. , Hodge, David O. , Riegert‐Johnson, Douglas L. , Hines, Stephanie L., Clift, Kristin E, Riegert-Johnson, Douglas, Clift, Kristin , Maimone, Santo

Mayo Clinic

Journal of Genetic Counseling | December 7, 2022 | Volume: 32 | Issue: 3 | Pages: 598-606

10.1002/jgc4.1665 | PMID 36478495 Get It

AbstractAdvances have dated the genetic testing initially offered to evaluate for hereditary breast and ovarian cancer risks. Previous research has demonstrated that many patients have not updated testing. This study reviewed the incidence of additional analysis after an uninformative BRCA1/2 result and offered updated testing with limited barriers to those who had not completed. After viewing an educational video and providing informed consent, eligible patients were mailed a saliva collection kit to complete an 84‐gene hereditary cancer panel at no personal cost. A total of 704 patients had completed BRCA1/2 only testing between 2001 and 2020. Fifteen percent (N = 102) of the 671 patients with an uninformative BRCA1/2 result had already completed expanded testing. Most, 74 of 102 (73%), had been rereferred to medical genetics during a clinical visit related to cancer care. Those who had already completed additional testing were more likely to have a personal history of cancer (92% vs. 79%, p = 0.002) and live locally (p = 0.032). Invitation to complete updated testing through this study was sent to 372 people, and 116 (31%) consented to participate. For 142 of the 256 who did not proceed with testing through the study, proof of receipt of research information was available. In total, 22 pathogenic variants were reported in 21 of the 226 patients with updated testing from before and including our study: ATM (4), CHEK2 (4), LZTR1 (1), MUTYH (3), NBN (1), NF1 (1), NTHL1 (1), PALB2 (4), PMS2 (1), RAD50 (1), and SPINK1 (1). Many potential barriers of retesting were eliminated by removing personal costs or travel requirements. Still, only about 30% of patients agreed to participate, and a significant portion elected not to proceed. Future research could focus on the discovery of other factors that dissuade patients and what measures may better inform them on potential benefits.